Full-text case series, number of patients, anticoagulant and indication for anticoagulation
| Case series | N | Anticoagulant, n (%) | Indication, n (%) | Bleed location, n (%) | ||||||
| A | Ed | R | AF | DVT/PE | Other | ICH | GI | Other | ||
| Barra et al20 | 11 | 3 (27) | 0 (0) | 8 (73) | 8 (73) | 3 (27) | NR | 11 (100) | 0 (0) | 0 (0) |
| Korobey et al25 | 59 | 40 (68) | 0 (0) | 19 (32) | 49 (83) | 16 (27) | NR | 59 (100) | 0 (0) | 0 (0) |
| Reynolds et al27 | 31 | 14 (45) | 0 (0) | 17 (55) | 22 (71) | 6 (19) | 3 (10) | 17 (55) | 7 (23) | 7 (23) |
| Arachchillage et al19 | 80 | 40 (50) | 0 (0) | 40 (50) | 68 (85) | 13 (16) | 0 (0) | 46 (58) | 24 (30) | 10 (13) |
| Dybdahl et al21 | 35 | 17 (49) | 0 (0) | 18 (51) | 31 (89) | 5 (14) | 0 (0) | 35 (100) | 0 (0) | 0 (0) |
| Frontera et al22 | 46 | 31 (67) | 0 (0) | 15 (33) | 44 (96) | 3 (7) | NR | 35 (76) * | 11 (24) | 0 (0) |
| Smith et al31 | 31 | 17 (55) | 0 (0) | 14 (45) | 28 (90) | 3 (10) | NR | 18 (58) | 1 (3) | 12 (39) |
| Allison et al18 | 33 | 6 (18. | 0 (0) | 27 (82) | 24 (73) | 6 (18) | 3 (9) | 30 (91) | 1 (3) | 2 (6) |
| Harrison et al24 | 14 | NR | NR | NR | 12 (86) | 3 (21) | 2 (14) | 14 (100) | 0 (0) | 0 (0) |
| Schenk et al28 | 13 | 0 (0) | 0 (0) | 13 (100) | NR | NR | NR | 10 (77) | 1 (8) | 2 (15) |
| Schulman et al29 | 66 | 29 (44) | 0 (0) | 37 (56) | 56 (85) | 10 (15) | 1 (2) | 36 (55) | 16 (24) | 15 (21) |
| Sheikh-Taha30 2018 | 29 | 13 (45) | 0 (0) | 16 (55) | 23 (79) | 5 (17) | 1 (3) | 21 (72) | 4 (14) | 4 (14) |
| Majeed et al26 | 84 | 39 (46) | 0 (0) | 45 (54) | 67 (80) | 21 (25) | 21 (25) | 59 (70) | 13 (16) | 12 (14) |
| Grandhi et al23 | 18 | 2 (11) | 0 (0) | 16 (89) | 16 (89) | 1 (6) | 3 (17) | 18 (100) | 0 (0) | 0 (0) |
*Study pooled intracranial haemorrhage and intraspinal bleed.
A, apixaban; AF, atrial fibrillation; DVT, deep vein thromboembolism; Ed, edoxaban; GI, gastrointestinal; ICH, intracranial haemorrhage; NR, not recorded; PE, pulmonary embolism; R, rivaroxaban.